search button

A retrospective study on intensity‑modulated radiation therapy combined with chemotherapy after D2 radical surgery for gastric carcinoma

  • Authors:
    • Wenguang Luo
    • Hongyan Zhang
    • Yufei Zhao
    • Lin Wang
    • Lijun Qi
    • Jingjing Ran
    • Lei Liu
    • Aidong Wu

  • View Affiliations

  • Published online on: March 7, 2016     https://doi.org/10.3892/mco.2016.804
  • Pages: 740-748
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In order to investigate the clinical value of different chemotherapies, the efficacy of intensity‑modulated radiation therapy with concurrent chemotherapy following D2 radical surgery for gastric carcinoma was evaluated in this study. A total of 102 patients who underwent D2 radical surgery for gastric carcinoma followed by concurrent chemoradiotherapy (CRT) between January, 2008 and March, 2012, were selected. The 5/7 field intensity‑modulated radiation therapy was used, with a planning target volume dose of 45 Gy in 25 fractions over 5 weeks. Among these patients, 45 were administered 400 mg̸m2̸day fluorouracil and 20 mg̸m2̸day tetrahydrofurfuryl alcohol through intravenous infusion 4 days before and 3 days after the radiotherapy (F‑CRT group), while 57 patients received 825 mg/m2 capecitabine orally twice a day (C‑CRT group). The 3‑year overall and the disease‑free survival rates were 75.5 and 70.5%, respectively. The overall 3‑year survival rates of the F‑CRT and C‑CRT groups were 72.2 and 78.5% (P>0.05), respectively, and the 3‑year disease‑free survival rates were 67.7 and 72.8% (P>0.05), respectively. No significant differences were observed between the two groups. However, during the concurrent CRT, significant differences were found in the incidence of grade 1‑2 haematological toxicity between the F‑CRT and C‑CRT groups (73.3 vs. 50.9%, respectively; χ2 =5.320, P=0.021). Significant differences were also found in the incidence of grade 1‑2 gastrointestinal reactions between the two groups (77.8 vs. 57.9%, respectively; χ2=4.474, P=0.034). Therefore, intensity‑modulated radiation therapy combined with concurrent chemotherapy following D2 radical surgery for gastric cancer was found to be safe and effective. In addition, radiotherapy was better tolerated and more likely to be completed using C‑CRT rather than F‑CRT.
View Figures
View References

Related Articles

Journal Cover

May-2016
Volume 4 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 1.2
  • Ranked
    (total number of cites)
  • CiteScore: 2.6
  • CiteScore Rank: Q3: #242/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.693
  • SCImago Journal Rank (SJR): 0.393
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Luo W, Zhang H, Zhao Y, Wang L, Qi L, Ran J, Liu L and Wu A: A retrospective study on intensity‑modulated radiation therapy combined with chemotherapy after D2 radical surgery for gastric carcinoma. Mol Clin Oncol 4: 740-748, 2016
APA
Luo, W., Zhang, H., Zhao, Y., Wang, L., Qi, L., Ran, J. ... Wu, A. (2016). A retrospective study on intensity‑modulated radiation therapy combined with chemotherapy after D2 radical surgery for gastric carcinoma. Molecular and Clinical Oncology, 4, 740-748. https://doi.org/10.3892/mco.2016.804
MLA
Luo, W., Zhang, H., Zhao, Y., Wang, L., Qi, L., Ran, J., Liu, L., Wu, A."A retrospective study on intensity‑modulated radiation therapy combined with chemotherapy after D2 radical surgery for gastric carcinoma". Molecular and Clinical Oncology 4.5 (2016): 740-748.
Chicago
Luo, W., Zhang, H., Zhao, Y., Wang, L., Qi, L., Ran, J., Liu, L., Wu, A."A retrospective study on intensity‑modulated radiation therapy combined with chemotherapy after D2 radical surgery for gastric carcinoma". Molecular and Clinical Oncology 4, no. 5 (2016): 740-748. https://doi.org/10.3892/mco.2016.804